The global Inhalation Anesthesia Market is estimated to witness a CAGR of 3.5% between 2019 and 2025. The factors boosting the market include increasing occurrence of cancer, respiratory ailments, cardiovascular ailments, gastrointestinal problems, and neurological disorders. The latest trend in this regard is demand from the developing economies like India as it is becoming a hub of road mishaps.
These accidents ask for surgery; which, in turn, drives the demand for anesthesia. Inhalation anesthesia is preferred over injectable anesthesia as it proves to be less painful.
Desflurane, isoflurane, and sevoflurane constitute the inhalation anesthesia market in liquid form and xenon, cyclopropane, and nitrous oxide in the gaseous form. They are used to induce and maintain anesthesia during surgeries. Sevoflurane does hold the highest market share; thanks to its cost-effectiveness, high potency, and therapeutic advantages. On the other note, isoflurane is expected to grow at the fastest pace as geriatric population is on the rise worldwide and it smoothens the cardiac surgeries.
As far as geography is concerned, North America rules the roost due to immediate adoption of medical innovation, increasing number of chronic diseases, and strong reimbursement. Europe follows suit. Asia Pacific is likely to grab the maximum market share due to the reasons stated above.
At the same time, the market is subject to restraints in the form of ill-effects of anesthetic gases. It has been reported that these gases do add around 1% of CO2 to the atmosphere; thereby contributing to environmental imbalance. Novel techniques and methods are on the anvil for reprocessing and reutilizing anesthetic gases. Anesthesia Reclamation LLC and Deltasorb Technologies are into creation of recycling systems.
Access full research report on global inhalation anesthesia market: https://www.millioninsights.com/industry-reports/inhalation-anesthesia-market-size
Some of the key facts from the report:
• Sevoflurane was the torchbearer in 2018; valued at $768.6 Million.
• Isoflurane is expected to grow at the quickest CAGR of 6.3% due to demand from geriatric patients.
• North America accounted for $456 Million in 2018 due to healthcare being prioritized all across the U.S. and Canada.
• The players contributing to the market include AbbVie Inc.; Fresenius Kabi AG; Jiangsu Hengrui Medicine Co. Ltd.; Piramal Enterprises Limited; Lunan Pharmaceutical Group Co. Ltd.; Hikima Pharmaceuticals PLC; Baxter; and Halocarbon Products Corporation.
Research Support Specialist, USA
Email: [email protected]